Park K, Lewanski C, Gadgeel SM, et al. 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR). 18th World Conference on Lung Cancer (WCLC) 2017, abstract MA 10.03.
PET-scan toont effect van bevacizumab bij kinderen met diffuus intrinsiek ponsglioom
mei 2017 | Neuro-oncologie